Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Schering Looks Overseas, Under Couch To Sustain Growth As Vytorin Stumbles

  • News

Executive Summary

Schering-Plough's strategy for reducing its elevated cholesterol worries depends on the firm capitalizing on one industry trend while bucking a few others

You may also be interested in...



Biologics Help Wyeth, Schering Blunt The Pain Of Tough U.S. Market

Strong sales of biologics and global diversification buttressed both Wyeth and Schering-Plough - at least partially - against a tough U.S. operating environment in the third quarter and first nine months of 2008

Biologics Help Wyeth, Schering Blunt The Pain Of Tough U.S. Market

Strong sales of biologics and global diversification buttressed both Wyeth and Schering-Plough - at least partially - against a tough U.S. operating environment in the third quarter and first nine months of 2008

Plavix, Oncologics Are Top Global Growth Stories Of 2007, IMS Reports

Despite slowing growth, 2007 witnessed the greatest increase in prescription drug sales ever, according to IMS Health data

Table

View full table

Related Content

Pink Sheet
In Vivo
Pink Sheet
Tags:
Latest Headlines

Finding The Sweet Spot For Real-World Evidence: Aetion Stresses Early Feasibility Assessment

FDA Gene Therapy Office Chief Prefers Flexibility With Accelerated Approval Confirmatory Trials

Keeping Track: Return & Renewal At US FDA

Korean Bioclusters Offer Tax, Other Incentives To Attract Global Firms, Talent

See All
UsernamePublicRestriction

Register

PS049568

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By